Astellas Announced Presentation of 21 Abstracts at ESMO 2026 Including Prostate, Urothelial, GEJ, Lung and Pancreatic cancers ...

I reject the idea that a man who keeps every prostate cancer surveillance appointment has ‘untreated cancer,’” writes Howard ...

Sanoj Punnen, M.D., a urologic oncologist at Sylvester Comprehensive Cancer Center and Vice Chair of Research at Desai Sethi Urology Institute, part of UHealth, the University of Miami Health System, ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...

PACE is the first phase 3 randomized trial directly comparing radical prostatectomy with SBRT in men with low- to intermediate-risk prostate cancer.

RARE prostate cancer nomograms showed strong performance in predicting one-, three-, and five-year overall survival (OS) and ...

Resero Bio, a precision diagnostics company building a cell-free RNA (cfRNA) liquid biopsy platform, today announced publication of a Stanford-led study in Nature Medicine demonstrating that analysis ...

Prostate cancer has a well-earned reputation for being one of the more trackable malignancies in medicine. Since the mid-1980s, a single blood test measuring prostate-specific antigen, or PSA, has ...

Prostate cancer screening generally begins around age 50, while men at higher risk may consider starting earlier, closer to ...

EHS leadership encouraged men to get regular screenings, which the hospital provides periodically throughout the year for ...

When prostate cancer returns or is at high risk of returning after surgery, radiation to the prostate bed (the area where the prostate used to be) is often recommended. The standa ...